Abstract | BACKGROUND: METHODS: In TRA 2°P-TIMI 50--a randomised, placebo-controlled, parallel trial--we randomly assigned patients with a history of atherothrombosis to receive vorapaxar (2·5 mg daily) or matching placebo in a 1:1 ratio. Patients, and those giving treatment, assessing outcomes, and analysing results were masked to treatment allocation. Patients with a qualifying myocardial infarction within the previous 2 weeks to 12 months were analysed as a pre-defined subgroup. The primary efficacy endpoint was cardiovascular death, myocardial infarction, or stroke, analysed by intention to treat. We analysed events by Kaplan-Meier analysis and compared groups with a Cox proportional hazard model. TRA 2°P-TIMI 50 is registered at ClinicalTrials.gov (NCT00526474). FINDINGS: 17,779 of 26,449 patients had a qualifying myocardial infarction and were assigned treatment (8898 to vorapaxar and 8881 to placebo). Median follow-up was 2·5 years (IQR 2·0-2·9). Cardiovascular death, myocardial infarction, or stroke occurred in 610 of 8898 patients in the vorapaxar group and 750 of 8881 in the placebo group (3-year Kaplan-Meier estimates 8·1%vs 9·7%, HR 0·80, 95% CI 0·72-0·89; p<0·0001). Moderate or severe bleeding was more common in the vorapaxar group versus the placebo group (241/8880 [3·4%, 3-year Kaplan-Meier estimate] vs 151/8849 [2·1%, 3-year Kaplan-Meier estimate], HR 1·61, 95% CI 1·31-1·97; p<0·0001). Intracranial haemorrhage occurred in 43 of 8880 patients (0·6%, 3-year Kaplan-Meier estimate) with vorapaxar versus 28 of 8849 (0·4%, 3-year Kaplan-Meier estimate) with placebo (p=0·076). Other serious adverse events were equally distributed between groups. INTERPRETATION: FUNDING: Merck.
|
Authors | Benjamin M Scirica, Marc P Bonaca, Eugene Braunwald, Gaetano M De Ferrari, Daniel Isaza, Basil S Lewis, Felix Mehrhof, Piera A Merlini, Sabina A Murphy, Marc S Sabatine, Michal Tendera, Frans Van de Werf, Robert Wilcox, David A Morrow, TRA 2°P-TIMI 50 Steering Committee Investigators |
Journal | Lancet (London, England)
(Lancet)
Vol. 380
Issue 9850
Pg. 1317-24
(Oct 13 2012)
ISSN: 1474-547X [Electronic] England |
PMID | 22932716
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Elsevier Ltd. All rights reserved. |
Chemical References |
- Lactones
- Pyridines
- Receptor, PAR-1
- vorapaxar
|
Topics |
- Aged
- Cardiovascular Diseases
(mortality)
- Double-Blind Method
- Female
- Humans
- Lactones
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Myocardial Infarction
- Pyridines
(adverse effects, therapeutic use)
- Receptor, PAR-1
(antagonists & inhibitors)
- Secondary Prevention
- Stroke
(etiology, prevention & control)
- Thrombosis
(complications, etiology, prevention & control)
|